Pharma Pipeline Advances Dominate Monday Trading

Lilly posts Phase 3 win, Regeneron expands partnerships, FDA grants priority review to MRK

Healthcare Market Overview

Healthcare stocks captured investor attention Monday with multiple pipeline developments and partnership announcements across Big Pharma. Eli Lilly ($LLY) attracted GARP investor interest with strong growth and reasonable valuation metrics, while analysts debate opportunities in sectors outside the Magnificent Seven, including healthcare names like Johnson & Johnson ($JNJ) and UnitedHealth ($UNH).

Big Pharma & Biotech

Eli Lilly ($LLY) reported significant progression-free survival extension for Jaypirca (pirtobrutinib) when added to venetoclax in previously treated CLL/SLL patients, marking the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm. Regeneron ($REGN) announced a strategic 50/50 cost and profit-sharing radiopharmaceutical collaboration with Telix, combining Regeneron's antibody platform with Telix's radiopharma expertise. AbbVie ($ABBV) entered an exclusive licensing agreement with Haisco for novel pain medicines covering global rights excluding mainland China, Hong Kong, and Macau, and showcased Phase 2 data for mirvetuximab soravtansine-gynx in platinum-sensitive ovarian cancer, achieving a 62.7% objective response rate.

MedTech & Devices

Intuitive Surgical ($ISRG) was highlighted among three stocks positioned to outperform over the next decade, though no specific product or operational updates were detailed. The surgical robotics leader continues to attract long-term investor interest based on its market position and growth trajectory.

FDA & Regulation

Merck ($MRK) received FDA Priority Review for ifinatamab deruxtecan in adult patients with previously treated extensive-stage small cell lung cancer who progressed on or after platinum-based chemotherapy, based on results from the IDeate-Lung01 Phase 2 trial with support from IDeate-PanTumor01 data. If approved, the candidate would be a first-in-class B7-H3 directed DXd antibody drug conjugate. The European Commission approved Regeneron and Sanofi's Dupixent for moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years, marking the first targeted medicine for young children with CSU based on data from the LIBERTY-CUPID clinical trial program.

Looking Ahead

Market participants await first-quarter earnings from Johnson & Johnson ($JNJ) later this week as part of the broader earnings season kickoff. Pfizer ($PFE) faces continued analyst scrutiny after BofA lowered its price target to $26 from $27 while maintaining a Neutral rating, reflecting Q1 preview updates across large-cap pharma. Amgen ($AMGN) settled BPCIA litigation with Shanghai Henlius and Organon concerning denosumab biosimilars, with a consent order entered March 31, 2026 in New Jersey District Court.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy